Applicant: David Alland, et al.

Serial No.: 09/918,951 Filed: July 31, 2001

Page 2

Claim Amendments

1-45 (canceled)

46 (currently amended): A method of determining whether a drug or compound is effective against *Mycobacterium tuberculosis* comprising:

- (a) transforming, into a mycobacterium, a vector construct comprising thea nucleotide sequence of thea Mycobacterium tuberculosis iniB promoter inserted into a plasmid-into a mycobacterium;
 - (b) culturing the mycobacterium:;
 - (c) treating the cultured cellsmycobacterium with the drug; and
- (d) measuring induction of the iniB promoter, the presence of induction indicating the drug is effective against *Mycobacterium tuberculosis*.

47 (withdrawn)

48 (previously added): The method of claim 46, wherein the mycobacterium is selected from the group consisting of *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium smegmatis*, *Mycobacterium bovis BCG*, *Mycobacterium leprae*, *Mycobacterium africanium*, and *Mycobacterium intracellulare*.

49 (previously added): The method of claim 46, wherein the induction of the iniB promoter causes the expression of a reporter gene.

50 (previously added): The method of claim 49, wherein the reporter gene is selected from the group consisting of lacZ and luciferase.

Applicant: David Alland, et al.

Serial No. : 09/918,951 Filed : July 31, 2001

Page 3

51 (currently amended): the The method of claim 46, wherein the drug or compound is effective against the biosynthesis of the *Mycobacterium tuberculosis* cell wall.

52 (new): The method of claim 46, wherein the nucleotide sequence of the iniB promoter comprises SEQ ID NO:1 and nucleotides 1-159 of SEQ ID NO:2.